Ultragenyx Pharmaceutical Inc. (RARE) income statement
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$16.48−0.74 (-4.30%)
Close on Nov 20, 2026Market cap $1.62BP/E –Yield –
Ultragenyx Pharmaceutical Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -73.6%
- Net margin
- -81.7%
- Return on equity, FY2025
- -657.1%
Financial strength
- Current ratio
- 1.73
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 35.6%
Valuation
- P/E ratio
- –
- Price to sales
- 2.27
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?